Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M17,715Revenue $M6,909Net Margin (%)8.1Z-Score1.9
Enterprise Value $M25,764EPS $1.6Operating Margin %15.1F-Score4
P/E(ttm))32.5Cash Flow Per Share $3.2Pre-tax Margin (%)9.5Higher ROA y-yN
Price/Book5.310-y EBITDA Growth Rate %12.7Quick Ratio1.0Cash flow > EarningsY
Price/Sales2.65-y EBITDA Growth Rate %7.1Current Ratio1.7Lower Leverage y-yN
Price/Cash Flow8.5y-y EBITDA Growth Rate %-7.0ROA % (ttm)4.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)18.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M374ROI % (ttm)4.4Gross Margin Increase y-yY

Gurus Latest Trades with MYL

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MYLJean-Marie Eveillard 2014-06-30 Add0.07%$45.72 - $52.1
($49.11)
$ 47.62-3%Add 83.88%1,241,991
MYLScott Black 2014-06-30 Reduce-0.4%$45.72 - $52.1
($49.11)
$ 47.62-3%Reduce -26.46%201,925
MYLJean-Marie Eveillard 2014-03-31 Buy 0.09%$42.26 - $57.2
($48.38)
$ 47.62-2%New holding, 675428 sh.675,428
MYLDavid Dreman 2014-03-31 Sold Out $42.26 - $57.2
($48.38)
$ 47.62-2%Sold Out0
MYLJohn Hussman 2014-03-31 Reduce-0.47%$42.26 - $57.2
($48.13)
$ 47.62-1%Reduce -75%50,000
MYLScott Black 2014-03-31 Reduce-0.16%$42.26 - $57.2
($48.13)
$ 47.62-1%Reduce -10.63%274,571
MYLJoel Greenblatt 2014-03-31 Sold Out -0.01%$42.26 - $57.2
($48.38)
$ 47.62-2%Sold Out0
MYLJoel Greenblatt 2013-12-31 Reduce$37.865 - $44.5
($41.09)
$ 47.6216%Reduce -31.83%7,291
MYLDavid Dreman 2013-12-31 Buy $37.865 - $44.5
($41.09)
$ 47.6216%New holding, 1221 sh.1,221
MYLJohn Hussman 2013-12-31 Reduce-0.53%$37.865 - $44.5
($41.09)
$ 47.6216%Reduce -55.95%200,000
MYLScott Black 2013-12-31 Reduce-0.23%$37.865 - $44.5
($41.09)
$ 47.6216%Reduce -14.62%307,214
MYLJohn Hussman 2013-09-30 Reduce-0.48%$30.37 - $38.95
($35.23)
$ 47.6235%Reduce -43.25%454,000
MYLJoel Greenblatt 2013-09-30 Reduce-0.16%$30.37 - $38.95
($35.23)
$ 47.6235%Reduce -91.73%10,695
MYLRay Dalio 2013-09-30 Sold Out -0.02%$30.37 - $38.95
($35.23)
$ 47.6235%Sold Out0
MYLJohn Hussman 2013-06-30 Buy 1.1%$27.96 - $31.87
($29.87)
$ 47.6259%New holding, 800000 sh.800,000
MYLJoel Greenblatt 2013-06-30 Add0.15%$27.96 - $31.87
($29.87)
$ 47.6259%Add 668.47%129,295
MYLMario Gabelli 2013-06-30 Reduce$27.96 - $31.87
($29.87)
$ 47.6259%Reduce -35.28%13,000
MYLJohn Paulson 2013-06-30 Reduce-0.98%$27.96 - $31.87
($29.87)
$ 47.6259%Reduce -32.83%12,139,300
MYLRay Dalio 2013-06-30 Reduce-0.06%$27.96 - $31.87
($29.87)
$ 47.6259%Reduce -79.15%61,097
MYLVanguard Health Care Fund 2013-03-31 Buy 0.48%$27.45 - $31.01
($29.03)
$ 47.6264%New holding, 4176100 sh.4,176,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MYL is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
MYL Jean-Marie Eveillard 2014-06-301,241,9910.330.16+83.88%
MYL Mario Gabelli 2014-06-3013,80000+6.15%
MYL John Paulson 2014-06-3012,130,7003.252.7
MYL John Hussman 2014-06-3050,0000.010.2
MYL Vanguard Health Care Fund 2014-06-304,775,7001.280.65
MYL Scott Black 2014-06-30201,9250.051.5-26.46%
Premium Most recent portfolio changes are included for Premium Members only!


MYL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
DIMICK NEIL FDirector 2014-09-18Sell5,432$48.26-1.33view
DIMICK NEIL FDirector 2014-06-19Sell5,432$50.81-6.28view
Malik RajivPresident 2014-04-22Sell80,000$50-4.76view
BRESCH HEATHER MCEO 2014-04-14Sell75,000$46.073.36view
DIMICK NEIL FDirector 2014-03-20Sell5,813$53.08-10.29view
TODD C BDirector 2014-03-14Sell10,000$53-10.15view
MAROON JOSEPH C MDDirector 2014-03-10Sell10,000$53.51-11.01view
KORMAN HARRYCOO 2014-03-06Sell31,970$54.54-12.69view
Mauro AnthonyPresident, North America 2014-03-03Sell20,000$54.81-13.12view
LEECH DOUGLAS JDirector 2014-03-03Sell10,000$55.4-14.04view

Press Releases about MYL :

    Quarterly/Annual Reports about MYL:

    News about MYL:

    Articles On GuruFocus.com
    Scott Black’s Top First Quarter Holdings Apr 23 2014 
    Should You Buy Actavis? Mar 18 2014 
    Scott Black’s Top Five Stocks at Year End Jan 09 2014 
    Scott Black’s Top Five Third Quarter Holdings Oct 22 2013 
    S&P Winners Broadly Held by Billionaires Oct 06 2013 
    Weekly CEO Sells Highlight: Workday Inc., Kirby Corp., Mylan Inc., Infinera Corporation Sep 09 2013 
    Three Stocks for a Recovering Europe Jul 29 2013 
    comment on MYL Jan 03 2013 
    comment on MYL Jan 01 2013 
    Weekly Top Insider Sells: FIS, MYL, LMCA Dec 24 2012 


    More From Other Websites
    Vikings bar Peterson from all team activities Sep 17 2014
    Vikings bar Peterson from all team activities Sep 17 2014
    [$$] Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries Sep 16 2014
    Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin... Sep 16 2014
    [video] Gilead Expands Access of Hepatitis C Drug in Developing Countries Sep 15 2014
    Gilead to license generic version of Sovaldi Sep 15 2014
    Gilead to license generic version of Sovaldi Sep 15 2014
    Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi®... Sep 15 2014
    Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others Sep 15 2014
    ABB CEO Says Company ‘Too Big to Swallow’ in Tax Inversion Deal Sep 12 2014
    The Zacks Analyst Blog Highlights: Mylan, Abbott Laboratories, Mallinckrodt, Gilead Sciences and... Sep 12 2014
    Mylan to Acquire U.S. Rights to Arixtra for up to $300M Sep 11 2014
    Top U.S. Senate Democrats unveil earnings stripping plan Sep 10 2014
    [$$] Counsel to Cuomo Steps Down Sep 10 2014
    S.Africa's Aspen to sell U.S. drug rights to Mylan for up to $300 mln Sep 10 2014
    [video] Sen. Schumer's inversion compromise Sep 10 2014
    Burlington Stores, Quiksilver, Hospira, Mylan and Gilead Sciences highlighted as Zacks Bull and Bear... Sep 10 2014
    Mylan to Acquire U.S. Rights to Arixtra® (fondaparinux sodium) Injection from Aspen Sep 10 2014
    Hospira Down on Legal Blow; Court Allows Generic Precedex Sep 09 2014
    [video] Pursuing tax inversion solutions Sep 08 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK